Market Overview

UPDATE: Goldman Sachs Downgrades Vertex Pharmaceuticals to Sell on CF Combo Outlook

Related VRTX
18 Stocks Moving In Wednesday's Pre-Market Session
15 Stocks Which Plummeted Three Days On Increasing Volume
Galapagos Cystic Fibrosis Drug Trails Vertex's 'Mega-Franchise': RBC (Investor's Business Daily)

Goldman Sachs lowered its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Sell and reduced its price target from $55 to $43.

Goldman Sachs noted, "We downgrade shares of VRTX to Sell from Neutral following 3Q12 results and the NACFC conference earlier this month, as we have a more cautious outlook on the company's key pipeline program (cystic fibrosis, CF combo) and see a limited number of catalysts heading into 2013. In our view, success of the CF pipeline is key to driving outer-year growth as VRTX's existing revenue base slows. We model a 10% revenue CAGR (2012-2015) if CF combo succeeds vs. -2% if it fails vs. peer group mean CAGRs of 15%-20%."

Vertex Pharmaceuticals closed at $50.48 on Thursday.

Latest Ratings for VRTX

Oct 2016H.C. WainwrightDowngradesBuyNeutral
Oct 2016JefferiesMaintainsBuy
Sep 2016JefferiesMaintainsBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!